Humana (HUM)
(Delayed Data from NYSE)
$395.60 USD
+11.39 (2.96%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $395.59 -0.01 (0.00%) 7:26 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Humana (HUM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$379.82 | $550.00 | $326.00 | -1.14% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Humana comes to $379.82. The forecasts range from a low of $326.00 to a high of $550.00. The average price target represents a decline of 1.14% from the last closing price of $384.21.
Analyst Price Targets (22)
Broker Rating
Humana currently has an average brokerage recommendation (ABR) of 2.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 2.10 a month ago based on 21 recommendations.
Of the 23 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 43.48% and 4.35% of all recommendations. A month ago, Strong Buy made up 42.86%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 12 | 11 | 10 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.09 | 2.09 | 2.10 | 2.11 | 2.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Truist Securities | David S Macdonald | Hold | Hold |
6/26/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
6/18/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Hold | Hold |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Hold |
5/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/25/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/25/2024 | UBS | Kevin Caliendo | Hold | Hold |
4/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/8/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Hold | Hold |
4/3/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
3/22/2024 | Raymond James | John W Ransom | Hold | Hold |
3/12/2024 | Argus Research Corp. | David A Toung | Strong Buy | Hold |
3/6/2024 | Not Identified | Not Identified | Not Available | Hold |
11/1/2023 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.09 |
ABR (Last week) | 2.09 |
# of Recs in ABR | 23 |
Average Target Price | $379.82 |
LT Growth Rate | 10.60% |
Industry | Medical - HMOs |
Industry Rank by ABR | 177 of 252 |
Current Quarter EPS Est: | 5.89 |